{"filing":{"accession_number":"0001104659-26-069792","cik":"0001567892","ticker":null,"company_name":"Keenova Therapeutics plc","form":"8-K","filing_date":"2026-06-03","report_date":null,"primary_document":"tm2616735d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1567892/000110465926069792/tm2616735d1_8k.htm"},"events":[{"id":7079,"run_id":6210,"accession_number":"0001104659-26-069792","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This Item 5.07 disclosure presents the final voting results from Keenova Therapeutics plc's 2026 Annual General Meeting held on June 2, 2026, covering six proposals: election of nine directors, re-appointment of PricewaterhouseCoopers LLP as auditors, advisory vote on executive compensation, frequency of future compensation votes, reduction of capital, and amendment to articles of association. The tabular presentation of FOR/AGAINST/ABSTAIN votes for each proposal is the hallmark of shareholder vote results disclosure.","company_name":"Keenova Therapeutics plc","ticker":null,"filing_date":"2026-06-03","form":"8-K","submitted_at":null,"items":[{"id":3859,"accession_number":"0001104659-26-069792","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure presents the final voting results from Keenova Therapeutics plc's 2026 Annual General Meeting held on June 2, 2026, covering six proposals: election of nine directors, re-appointment of PricewaterhouseCoopers LLP as auditors, advisory vote on executive compensation, frequency of future compensation votes, reduction of capital, and amendment to articles of association. The tabular presentation of FOR/AGAINST/ABSTAIN votes for each proposal is the hallmark of shareholder vote results disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:16:52.683801+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":3859,"accession_number":"0001104659-26-069792","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure presents the final voting results from Keenova Therapeutics plc's 2026 Annual General Meeting held on June 2, 2026, covering six proposals: election of nine directors, re-appointment of PricewaterhouseCoopers LLP as auditors, advisory vote on executive compensation, frequency of future compensation votes, reduction of capital, and amendment to articles of association. The tabular presentation of FOR/AGAINST/ABSTAIN votes for each proposal is the hallmark of shareholder vote results disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:16:52.683801+00:00","company_name":"Keenova Therapeutics plc","ticker":null,"filing_date":"2026-06-03"}]}